Loading stock data…
Belite Bio (BLTE)
$149.84+1.11 (+0.75%)
Market OpenUpdated 3:15 PM EDT
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Belite Bio, Inc in the Healthcare sector is trading at $149.84 with a market capitalization of $5.5B. Wall Street consensus targets $210.50 (8 analysts), implying a +40.5% move over the next 12 months. The stock is currently 25% below its 52-week high of $200.00, remaining 6.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +40.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$32.68M↓ | -$28.08M↓ | -$23.02M↓ | -$17.60M↓ | -$15.52M |
| Net Income | -$26.94M↓ | -$25.32M↓ | -$21.69M↓ | -$16.32M↓ | -$14.28M |
Peer Comparison
JNJUNHPFE
Fundamentals
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.34%
Volume
Today's trading volume
114,505
Recent News
We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Belite Bio...
Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses
Belite Bio Inc (BLTE) reports significant progress in clinical trials and commercial preparations, despite increased R&D and SG&A expenses.
Belite Bio Q1 Earnings Call Highlights
Belite Bio (NASDAQ:BLTE) said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations for a potential commercial launch. On the company’s first-quarter 2026 earnings call, Chairman and
Belite Bio (BLTE) Q1 2026 Earnings Transcript
Have received our Phase 3 clinical study report in Q1 without delay in April we initiated our NDA rolling submission to the FDA for Stargardt disease. As well as engaging with the retinal community to raise awareness of Stargardt disease. In line with that commitment to bring Tinlarebant to patients around the world, This past quarter, we also announced that we have completed enrollment in our Phase 2/3 Dragon 2 clinical trial evaluating Tinlarebant for Stargardt disease.
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE)
Belite Bio, Inc. (NASDAQ:BLTE) reported first-quarter results on Wednesday that came in ahead of analyst forecasts, with the clinical-stage biotech group posting an adjusted loss per share of -$0.